News & Events

Last Patient Last Visit (LPLV) reached in the SAPHIR Study

Last Patient Last Visit (LPLV) reached in the SAPHIR Study, a Phase 2 trial with the Glutaminyl Cyclase (QC) inhibitor PQ912 in early Alzheimer’s Disease (AD) […]

Probiodrug to attend International Conferences in April 2017

HALLE (SAALE), Germany, 03 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug reports full year 2016 financial results

SAPHIR, the Phase 2a study of PQ912 as a novel treatment for Alzheimer’s disease fully enrolled Favourable results of chronic toxicology studies with PQ912 announced Promising […]

Probiodrug to present at Alzheimer’s and Parkinson’s Diseases Congress

New results of a double pronged-approach to target the neurotoxic amyloid beta species pGlu-Abeta, and an evaluation of new biomarkers in cerebrospinal fluid (CSF) from AD […]

Probiodrug AG to Publish its Full Year 2016 Results on 30 March 2017

HALLE (SAALE), Germany, 23 March 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its Full […]

Probiodrug to attend and present at International Conferences in March 2017

HALLE (SAALE), Germany, 06 March 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]